GSK: depemokimab progress in Europe and Asia
(CercleFinance.com) - GSK announced on Tuesday that the European Medicines Agency (EMA) had agreed to review the marketing authorization application for its new treatment for asthma and chronic sinusitis, depemokimab.
The application is for approval of the drug in two indications, namely asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, says the British pharmaceutical company.
Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5) to reduce inflammation, has the advantage of a long duration of action, enabling it to be administered just twice a year.
Although depemokimab is not currently approved in any country, GSK points out that the Chinese and Japanese health authorities have also accepted the submission of a marketing authorization application for the candidate, again for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The application is for approval of the drug in two indications, namely asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, says the British pharmaceutical company.
Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5) to reduce inflammation, has the advantage of a long duration of action, enabling it to be administered just twice a year.
Although depemokimab is not currently approved in any country, GSK points out that the Chinese and Japanese health authorities have also accepted the submission of a marketing authorization application for the candidate, again for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
Copyright (c) 2025 CercleFinance.com. All rights reserved.